Clinical Trial News and Research

RSS

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).

30 Sep 2014

Galmed Pharmaceuticals purchases EndoPAT devices, accessories from Itamar Medical

Galmed Pharmaceuticals Ltd. ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today that it purchased 60 EndoPAT™ devices and accessories from Itamar Medical Ltd.

29 Sep 2014

Manzo Pharmaceuticals reports successful testing of lactase producing probiotic, Lacto-Freedom

Manzo Pharmaceuticals, Inc., today announced at the three month mark in a six month animal study, that the results of the lactase producing probiotic, Lacto-Freedom™, has been very successful.

29 Sep 2014

Curemark Founder to get Northstar Award for breakthrough autism research

Curemark, a leading drug research and development company focused on the treatment of neurological and other diseases, is proud to announce that Dr. Joan Fallon, Founder and CEO, will receive Springboard Enterprises' Northstar Award, as recognition for her entrepreneurial leadership and achievements in autism research.

29 Sep 2014

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung cancer and ovarian cancer.

29 Sep 2014

Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

The recent launch of two clinical trials offer innovative study designs for patients with lung cancer. These clinical trials are the direct result of a National Cancer Institute sponsored workshop chaired by Drs. Fred R. Hirsch, Shakun Malik and Claudio Dansky- Ullman, that brought together the NCI Thoracic Malignancies Steering Committee, the US Food and Drug Administration, academicians, clinicians as well as industry and government stakeholders to discuss issues and challenges related to clinical trial design and biomarkers for lung cancer targeted-therapies.

29 Sep 2014

CVRx Barostim neo System receives CE Mark approval from NSAI for treatment of heart failure

CVRx, Inc., a private medical device company, announced today it received CE Mark approval from the National Standards Authority of Ireland of the Barostim neo System for the treatment of heart failure.

29 Sep 2014

NIH-funded clinical trial aims to restore vision in people who have lost vision due to IIH

In an NIH-funded clinical trial, led at Saint Louis University by professor of ophthalmology Sophia Chung, M.D., researchers aim to bring sight back to those who have lost vision due to idiopathic intracranial hypertension.

29 Sep 2014

Lung cancer clinical trials exclude substantial proportion of patients due to prior cancer

Lung cancer clinical trials exclude a substantial proportion of patients due to a history of prior cancer, as shown in an analysis by cancer researchers at UT Southwestern Medical Center.

29 Sep 2014

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis.

29 Sep 2014

Heart Hospital of Austin becomes first facility in Texas to implant CardioMEMS HF System

On Sept. 24, 2014 Heart Hospital of Austin became the first facility in Texas to implant a new miniaturized, wireless monitoring sensor to manage heart failure (HF). The CardioMEMS HF System is the first and only FDA-approved heart failure monitoring device that has been proven to significantly reduce hospital admissions when used by physicians to manage heart failure.

27 Sep 2014

Australian researchers use hookworms to reduce symptoms of celiac disease

Australian researchers have achieved groundbreaking results in a clinical trial using hookworms to reduce the symptoms of celiac disease.

26 Sep 2014

MicroBiome Therapeutics' NM 505 drug can improve tolerability of metformin

MicroBiome TherapeuticsTM LLC, today reported positive topline results from a proof of concept study testing whether its investigational drug, NM 505, can improve the tolerability of metformin, the first-line therapy for Type 2 diabetes worldwide.

26 Sep 2014

AcelRx plans for resubmission of Zalviso NDA

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided an update on the plans for the resubmission of the Company's New Drug Application (NDA) for Zalviso (sufentanil sublingual tablet system).

26 Sep 2014

Sumitomo Dainippon Pharma, SanBio to jointly develop SB623 in the U.S. and Canada

Sumitomo Dainippon Pharma Co., Ltd. and SanBio Co., Ltd., acting through its U.S. subsidiary SanBio, Inc., announced on September 26 that the two companies have entered into a joint development and license agreement for exclusive marketing rights in the U.S. and Canada ("Agreement") for SB623, a cell therapy for the treatment of patients with chronic stroke discovered and currently under development by SanBio.

26 Sep 2014

CorMedix submits IND application to FDA for Neutrolin

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, is pleased to announce that an Investigational New Drug application (IND) for Neutrolin was submitted to the United States Food and Drug Administration on Wednesday, September 24, 2014.

25 Sep 2014

Women better informed about prenatal genetic testing choose fewer tests

A clinical trial led by UC San Francisco has found that when pregnant women are educated about their choices on prenatal genetic testing, the number of tests actually drops, even when the tests are offered with no out-of-pocket costs.

25 Sep 2014

NCCN ORP awards four research grants to advance development of nintedanib

The National Comprehensive Cancer Network Oncology Research Program has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal cancers.

25 Sep 2014

Treating prediabetes patients could help prevent severe complications associated with diabetes

Doctors at three leading research institutions and the American Diabetes Association report that treating patients with prediabetes as if they had diabetes could help prevent or delay the most severe complications associated with this chronic disease, which affects about thirty million people in the United States.

25 Sep 2014

Novel treatment makes life-saving difference to young patients with Ph-like ALL

St. Jude Children's Research Hospital investigators found that adjusting treatment based on early response to chemotherapy made a life-saving difference to young patients with an acute lymphoblastic leukemia (ALL) subtype associated with a poor outcome.

24 Sep 2014

Clinical Trial News and Research

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Galmed Pharmaceuticals purchases EndoPAT devices, accessories from Itamar Medical

Manzo Pharmaceuticals reports successful testing of lactase producing probiotic, Lacto-Freedom

Curemark Founder to get Northstar Award for breakthrough autism research

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

CVRx Barostim neo System receives CE Mark approval from NSAI for treatment of heart failure

NIH-funded clinical trial aims to restore vision in people who have lost vision due to IIH

Lung cancer clinical trials exclude substantial proportion of patients due to prior cancer

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Heart Hospital of Austin becomes first facility in Texas to implant CardioMEMS HF System

Australian researchers use hookworms to reduce symptoms of celiac disease

MicroBiome Therapeutics' NM 505 drug can improve tolerability of metformin

AcelRx plans for resubmission of Zalviso NDA

Sumitomo Dainippon Pharma, SanBio to jointly develop SB623 in the U.S. and Canada

CorMedix submits IND application to FDA for Neutrolin

Women better informed about prenatal genetic testing choose fewer tests

NCCN ORP awards four research grants to advance development of nintedanib

Treating prediabetes patients could help prevent severe complications associated with diabetes

Novel treatment makes life-saving difference to young patients with Ph-like ALL

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer